Vertex a buy into Phase 3 data for VX-809, says Deutsche Bank Deutsche Bank said it would be a buyer of Vertex shares into the company's mid-2014 Phase 3 data for VX-809. The firm expects the primary endpoint to be hit and thinks shares could trade to $103-$111 on good data. Deutsche says shares of Vertex could trade down to $30-$35 with a Phase 3 failure. It has a Buy rating on the stock with a $103 price target.
Gilead paying premium to buy Vertex not warranted right now, says Maxim After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.